Nordicus Partners Corporation Reports Increased Net Loss and No Revenue for Q2 2026

Nordicus Partners Corporation reported its financial results for the three months ended June 30, 2026, revealing a continued lack of revenue, consistent with the same period in the previous year. The company incurred a net loss of $2.3 million, compared to a loss of $1.2 million in the prior year. This increase in loss is attributed to higher operating expenses, particularly in officer compensation, which rose by 77% to $115,354, and other expenses related to changes in the fair value of investments, which totaled $1.5 million. The company’s total operating expenses for the quarter were $819,624, a slight decrease from $831,886 in the same quarter of 2025.

In terms of financial position, Nordicus reported total assets of approximately $73.1 million as of June 30, 2026, down from $75.5 million at the end of the previous quarter. The decline in assets was primarily due to a significant reduction in cash and prepaid expenses, which fell to $5.8 million and $292,618, respectively. The company’s accumulated deficit increased to $53.2 million, reflecting ongoing operational losses. Current liabilities also rose to $1.67 million, up from $1.17 million, largely due to increased accounts payable and accrued expenses.

Strategically, Nordicus has been active in expanding its portfolio through acquisitions. The company has focused on developing therapeutics for diseases with unmet medical needs, particularly in the oral health sector. Notable acquisitions include Orocidin A/S and Bio-Convert A/S, both of which are engaged in developing innovative treatments for periodontitis and oral leukoplakia, respectively. The company also formed a new subsidiary, NoviThera, aimed at developing a monoclonal antibody treatment for psoriasis. These strategic moves are part of Nordicus's broader goal to enhance its market position and drive future growth.

Operationally, Nordicus has not reported any revenue generation, as it remains in the pre-revenue phase. The company’s focus on research and development continues, with R&D expenses slightly increasing to $437,885, reflecting ongoing efforts in its subsidiaries. The company’s employee headcount remains stable, with no significant changes reported. However, the company faces challenges in liquidity, holding only $5,784 in cash as of the end of the reporting period, raising concerns about its ability to sustain operations without additional financing.

Looking ahead, Nordicus has indicated that its ability to continue as a going concern is contingent upon successfully executing its strategic plans, including potential financing through private placements of common stock. The company is actively seeking to raise capital to support its operations and fulfill its obligations. Management remains optimistic about the future, particularly with the anticipated start of clinical trials for its portfolio companies in 2027, which could pave the way for future revenue generation.